

Coronavirus Disease 2019 (COVID-19) Situation Report

Data as reported by national authorities by 24:00 local time 30 December 2020

Situation Report No. 204 - Kingdom of Bahrain
31th of December, 2020






	Global		Eastern Mediterranean Region	
	COVID-19 Cases	COVID-19 Deaths	COVID-19 Cases	COVID-19 Deaths
Total	80,773,033	1,783,619	4,885,422	120,339
New	563,983	11,784	22,206	451

Kingdom of Bahrain

	Confirmed Cases	Recovered Cases	Deaths	Active Cases	Critical Cases	PCR Tests
Total	92,425	90,062	352	2,047	10	2,355,313
New	256	222	1	-	-	9,988

HIGHLIGHTS

- The mortality was a 69 year old male Bahraini Citizens.
- Ministry of Health (MOH) revealed that total number of individuals vaccinated as of 30 December 2020 is 57,317.
- MOH Undersecretary reiterated that over one million vaccine doses have been on order since August, with Bahrain being globally amongst the first countries.
- MOH Undersecretary indicated that average number of daily new active cases as a percentage of daily COVID-19 tests during the first three weeks of December was approximately 1.5%, increasing to 2.4% from the 24th to 28th, reflecting an increase of 34% in the average of daily new active cases.
- MOH Undersecretary emphasized the importance of adhering to all precautionary measures, including limiting gatherings to members of same households or close social circle and utilizing outdoor open spaces, while observing social distancing guidelines.
- MOH Undersecretary revealed current COVID-19 recovery rate at 97.43% with about 0.38% case fatality rate; while occupancy at isolation centers stands at 8.9% with 540 beds occupied out of 6,078 available, and 1,474 asymptomatic cases are under optional home self-isolation.
- Infectious and Internal Diseases Experts in Bahrain stressed the importance of continuing to support national efforts to defeat COVID-19 by complying with all hygienic precautionary and social distancing measures, especially during the new year occasion, as well as wearing face masks in public.
- WHO: New research helps to increase understanding of the impact of COVID-19 for pregnant women and their babies; see link below.
- WHO: Guidance on Informing vaccination programs: a guide to the design and conduct of dengue sero-surveys; see link below.
- WHO: Responding to non-communicable diseases during and beyond the COVID-19 pandemic; see link below.
- WHO: Emergency Global Supply Chain System(COVID-19) catalogue; see link below.
- WHO: Interim guidance on Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassay; see link below.
- WHO: Global TB progress a trisk; see link below.
- WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination; see link below.
- WHO: Interim guidance Operational considerations for COVID-19 surveillance using GISRS; see link below.
- WHO: Statement by WHO Director of Programme Management on COVID-19 pandemic; see link below.
- WHO: As COVID-19 spread accelerates, JHR Emergency Committee urges focus on measures that work; see link below.
- WHO: The push for a COVID-19 vaccine; see link below.
- WHO-ICMRA joint statement on the need for improved global regulatory alignment on COVID-19 medicines and vaccines; see link below.
- WHO Living Guideline: The repurposes and COVID-19; see link below.
- WHO: Interim guidance on Diagnostics, therapeutics, vaccine readiness, and other health products for COVID-19; see link below.
- WHO: Evidence to recommendations: COVID-19 mitigation in the aviation sector; see link below.
- WHO: Health workforce policy and management in the context of the COVID-19 pandemic response; see link below.
- WHO: Checklist to support schools re-opening and preparation for COVID-19 resurgences or similar public health crises; see link below.
- WHO: COVID-19 vaccine introduction and deployment costing tool; see link below.
- WHO: Emergency Use Designation of COVID-19 candidate vaccines: Ethical considerations for current and future COVID-19 placebo-controlled vaccine trials and trial unblinding; see link below.
- WHO: Considerations for implementing a risk-based approach to international travel in the context of COVID-19; see link below.
- WHO: Risk assessment tool to inform mitigation measures for international travel in the context of COVID-19; see link below.
- WHO: COVAX Announces additional deals to access promising COVID-19 vaccine candidates; plans global rollout starting Q1 2021; see link below.
- WHO: Rational use of personal protective equipment for coronavirus disease (COVID-19) and considerations during severe shortages; see link below.



IMPORTANT LINKS

- Daily COVID-19 updates on MOH website: <https://www.moh.gov.bh/>
- WHO's COVID-19 weekly situation reports: https://www.who.int/docs/default-source/coronavirus/situation-reports/20200817-weekly-epi-update-1.pdf?sfvrsn=b6d4976_4
- WHO: COVID-19 Dashboard: <https://covid19.who.int/>
- WHO: New research helps to increase understanding of the impact of COVID-19 for pregnant women and their babies: <https://www.who.int/news-room/detail/01-09-2020-new-research-helps-to-increase-understanding-of-the-impact-of-covid-19-for-pregnant-women-and-their-babies>
- WHO: Guidance on Informing vaccination programs: a guide to the design and conduct of dengue sero-surveys: <https://www.who.int/publications/item/97892951413252-9>
- WHO: Responding to non-communicable diseases during and beyond the COVID-19 pandemic: <https://bit.ly/25vds0r>
- WHO: Emergency Global Supply Chain System(COVID-19) catalogue: [https://www.who.int/publications/item/emergency-global-supply-chain-system-\(covid-19\)-catalogue](https://www.who.int/publications/item/emergency-global-supply-chain-system-(covid-19)-catalogue)
- WHO: Interim guidance on Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays: <https://bit.ly/2H0jYf>
- WHO: Global TB progress a trisk: <https://bit.ly/34dx1H>
- WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination: <https://bit.ly/2J0wvWQ>
- WHO: Interim guidance Operational considerations for COVID-19 surveillance using GISRS: <https://bit.ly/34APNGG>
- WHO: Statement by WHO Director of Programme Management on COVID-19 pandemic: <https://bit.ly/3105DF>
- WHO: As COVID-19 spread accelerates, JHR Emergency Committee urges focus on measures that work: <https://bit.ly/372016>
- WHO: The push for a COVID-19 vaccine: <https://bit.ly/3m53haa>
- WHO-ICMRA joint statement on the need for improved global regulatory alignment on COVID-19 medicines and vaccines: <https://bit.ly/3panKSM>
- WHO Living Guideline: The repurposes and COVID-19: <https://www.who.int/publications/item/therapeutics-and-covid-19-living-guideline>
- WHO: Interim guidance on Diagnostics, therapeutics, vaccine readiness, and other health products for COVID-19: https://www.who.int/publications/item/WHO-2019-nCoV-HCF_assessment-Products-2020.1
- WHO: Evidence to recommendations: COVID-19 mitigation in the aviation sector: <https://www.who.int/publications/item/evidence-to-recommendation-covid-19-mitigation-in-the-aviation-sector>
- WHO: Health workforce policy and management in the context of the COVID-19 pandemic response: [file:///C:/Users/aldeir/Downloads/WHO-2019-nCoV-health_workforce-2020.1-eng.pdf](https://www.who.int/publications/item/WHO-2019-nCoV-health_workforce-2020.1-eng.pdf)
- WHO: Checklist to support schools re-opening and preparation for COVID-19 resurgences or similar public health crises: <https://www.who.int/publications/item/978929514017467>
- COVID-19 vaccine introduction and deployment costing tool: <https://www.who.int/publications/item/10665337553>
- WHO: Emergency Use Designation of COVID-19 candidate vaccines: Ethical considerations for current and future COVID-19 placebo-controlled vaccine trials and trial unblinding: https://www.who.int/publications/item/WHO-2019-nCoV-Policy_Brief-EUd_placebo-controlled_vaccine_trials-2020.1
- WHO: Considerations for implementing a risk-based approach to international travel in the context of COVID-19: https://www.who.int/publications/item/WHO-2019-nCoV-Risk-based_international_travel-Assessment_tool-2020.1
- WHO: Risk assessment tool to inform mitigation measures for international travel in the context of COVID-19: https://www.who.int/publications/item/WHO-2019-nCoV-Risk-based_international_travel-Assessment_tool-2020.1
- WHO: COVAX Announces additional deals to access promising COVID-19 vaccine candidates; plans global rollout starting Q1 2021: <https://www.who.int/news/item/18-12-2020-covax-announces-additional-deals-to-access-promising-covid-19-vaccine-candidates-plans-global-rollout-starting-q1-2021>
- WHO: Rational use of personal protective equipment for coronavirus disease (COVID-19) and considerations during severe shortages: [https://www.who.int/publications/item/rational-use-of-personal-protective-equipment-for-coronavirus-disease-\(covid-19\)-and-considerations-during-severe-shortages](https://www.who.int/publications/item/rational-use-of-personal-protective-equipment-for-coronavirus-disease-(covid-19)-and-considerations-during-severe-shortages)

IMPORTANT CONTACTS

- The National Focal Person is Dr. Najat Mohamed Abulfateh, email: NAI5@health.gov.bh
- International Health Regulations focal person is Dr. Kubra Salman, email: knasser@health.gov.bh